Advertisement

Topics

Boehringer Ingelheim Partners with Epizyme

18:50 EST 15 Nov 2018 | Investing News Network

Boehringer Ingelheim and Epizyme announced a partnership on Thursday to develop oncology treatments.The partnership entails developing, researching and commercializing small molecule inhibitors directed for two epigenetics targets as potential cancer therapies.

The post Boehringer Ingelheim Partners with Epizyme appeared first on Investing News Network.

Original Article: Boehringer Ingelheim Partners with Epizyme

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim Partners with Epizyme"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...